Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Seattle-based biotech Omeros Corp. (Nasdaq: OMER) has completed the sale of its Omidria franchise to the British eye care company Rayner Surgical Group Limited. In a release last week announcing the completion of the sale, Omeros said it received about $126 million in cash upfront. Between royalty payments and a commercial milestone payment of $200 million for Omidria, a drug that prevents excessive pupil constriction in cataract surgery, the companies project the deal to be worth over $1 bill...
SEATTLE, December 23, 2021--Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited. The transaction was completed pursuant to an Asset Purchase Agreement that was announced on December 2, 2021.
WHY: New York, N.Y., December 19, 2021. Rosen Law Firm, a global investor rights law firm, continues an investigation of potential securities claims on behalf of shareholders of Omeros Corporation (NASDAQ: OMER) resulting from allegations that Omeros may have issued materially misleading business information to the investing public.
Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
Los Angeles, California--(Newsfile Corp. - December 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or "the Company") (NASDAQ: OMER) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Omeros announced on October 1, 2021, that the FD
The deal includes a $125 million upfront payment and a commercial milestone payment of $200 million for Omidria, a drug used in cataract surgery.
SEATTLE, December 02, 2021--Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited. Expected to close on or before December 31, 2021, the transaction includes an upfront payment of $125 million with an additional $200 million in a commercial milestone payment. Omeros will also retain its accounts receivable balance at the closing, which was $34 million at the end of last quarter. Together with sub